These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
492 related articles for article (PubMed ID: 22031815)
1. Antiviral activity and increased host defense against influenza infection elicited by the human cathelicidin LL-37. Barlow PG; Svoboda P; Mackellar A; Nash AA; York IA; Pohl J; Davidson DJ; Donis RO PLoS One; 2011; 6(10):e25333. PubMed ID: 22031815 [TBL] [Abstract][Full Text] [Related]
2. Human cathelicidin LL-37-derived peptide IG-19 confers protection in a murine model of collagen-induced arthritis. Chow LN; Choi KY; Piyadasa H; Bossert M; Uzonna J; Klonisch T; Mookherjee N Mol Immunol; 2014 Feb; 57(2):86-92. PubMed ID: 24091294 [TBL] [Abstract][Full Text] [Related]
3. Cathelicidins Have Direct Antiviral Activity against Respiratory Syncytial Virus In Vitro and Protective Function In Vivo in Mice and Humans. Currie SM; Gwyer Findlay E; McFarlane AJ; Fitch PM; Böttcher B; Colegrave N; Paras A; Jozwik A; Chiu C; Schwarze J; Davidson DJ J Immunol; 2016 Mar; 196(6):2699-710. PubMed ID: 26873992 [TBL] [Abstract][Full Text] [Related]
6. The human cathelicidin LL-37 inhibits influenza A viruses through a mechanism distinct from that of surfactant protein D or defensins. Tripathi S; Tecle T; Verma A; Crouch E; White M; Hartshorn KL J Gen Virol; 2013 Jan; 94(Pt 1):40-49. PubMed ID: 23052388 [TBL] [Abstract][Full Text] [Related]
7. Cathelicidin antimicrobial peptides suppress EV71 infection via regulating antiviral response and inhibiting viral binding. Yu J; Dai Y; Fu Y; Wang K; Yang Y; Li M; Xu W; Wei L Antiviral Res; 2021 Mar; 187():105021. PubMed ID: 33508330 [TBL] [Abstract][Full Text] [Related]
8. The human cathelicidin LL-37 has antiviral activity against respiratory syncytial virus. Currie SM; Findlay EG; McHugh BJ; Mackellar A; Man T; Macmillan D; Wang H; Fitch PM; Schwarze J; Davidson DJ PLoS One; 2013; 8(8):e73659. PubMed ID: 24023689 [TBL] [Abstract][Full Text] [Related]
9. Cathelicidin deficiency predisposes to eczema herpeticum. Howell MD; Wollenberg A; Gallo RL; Flaig M; Streib JE; Wong C; Pavicic T; Boguniewicz M; Leung DY J Allergy Clin Immunol; 2006 Apr; 117(4):836-41. PubMed ID: 16630942 [TBL] [Abstract][Full Text] [Related]
10. Antiviral Activity of the Human Cathelicidin, LL-37, and Derived Peptides on Seasonal and Pandemic Influenza A Viruses. Tripathi S; Wang G; White M; Qi L; Taubenberger J; Hartshorn KL PLoS One; 2015; 10(4):e0124706. PubMed ID: 25909853 [TBL] [Abstract][Full Text] [Related]
11. Cathelicidin host defence peptide augments clearance of pulmonary Pseudomonas aeruginosa infection by its influence on neutrophil function in vivo. Beaumont PE; McHugh B; Gwyer Findlay E; Mackellar A; Mackenzie KJ; Gallo RL; Govan JR; Simpson AJ; Davidson DJ PLoS One; 2014; 9(6):e99029. PubMed ID: 24887410 [TBL] [Abstract][Full Text] [Related]
12. Liu Shen Wan inhibits influenza a virus and excessive virus-induced inflammatory response via suppression of TLR4/NF-κB signaling pathway in vitro and in vivo. Ma Q; Huang W; Zhao J; Yang Z J Ethnopharmacol; 2020 Apr; 252():112584. PubMed ID: 31972325 [TBL] [Abstract][Full Text] [Related]
13. Leukotriene B4 induces release of antimicrobial peptides in lungs of virally infected mice. Gaudreault E; Gosselin J J Immunol; 2008 May; 180(9):6211-21. PubMed ID: 18424743 [TBL] [Abstract][Full Text] [Related]
14. Human cathelicidin peptide LL-37 as a therapeutic antiviral targeting Venezuelan equine encephalitis virus infections. Ahmed A; Siman-Tov G; Keck F; Kortchak S; Bakovic A; Risner K; Lu TK; Bhalla N; de la Fuente-Nunez C; Narayanan A Antiviral Res; 2019 Apr; 164():61-69. PubMed ID: 30738837 [TBL] [Abstract][Full Text] [Related]
15. Cathelicidin and Calprotectin Are Disparately Altered in Murine Models of Inflammatory Arthritis and Airway Inflammation. Hemshekhar M; Piyadasa H; Mostafa D; Chow LNY; Halayko AJ; Mookherjee N Front Immunol; 2020; 11():1932. PubMed ID: 32973796 [TBL] [Abstract][Full Text] [Related]
16. Endogenous cathelicidin is required for protection against ZIKV-caused testis damage via inactivating virons. Liu Z; Wu J; Qin Z; Dong C; Yang H; Sun J; Xu W; Wei L Antiviral Res; 2022 Feb; 198():105248. PubMed ID: 35038500 [TBL] [Abstract][Full Text] [Related]
17. Unique features of human cathelicidin LL-37. Bandurska K; Berdowska A; Barczyńska-Felusiak R; Krupa P Biofactors; 2015; 41(5):289-300. PubMed ID: 26434733 [TBL] [Abstract][Full Text] [Related]
18. In-vitro effect of human cathelicidin antimicrobial peptide LL-37 on dengue virus type 2. Alagarasu K; Patil PS; Shil P; Seervi M; Kakade MB; Tillu H; Salunke A Peptides; 2017 Jun; 92():23-30. PubMed ID: 28400226 [TBL] [Abstract][Full Text] [Related]
19. LL-37 restored glucocorticoid sensitivity impaired by virus dsRNA in lung. Li K; Tao N; Zheng L; Sun T Int Immunopharmacol; 2020 Feb; 79():106057. PubMed ID: 31877496 [TBL] [Abstract][Full Text] [Related]